Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
EARLY_PHASE1
4
about 3.3 years
18+
1 site in OH
What this study is about
This trial is testing whether a new imaging agent called 18F-Clofarabine (CFA) can be used to image cancer metabolism. The goal is to see if CFA can measure deoxycytidine kinase activity, which helps determine how well certain cancer drugs are taken up by cancer cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 18F-Clofarabine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
injection (Injection)
Primary: Evaluate CFA as a PET imaging agent
Secondary: Adverse Events, Correlate CFA uptake with OS, Correlate CFA uptake with PFS, Correlate CFA uptake with conventional imaging
Oncology